SOLICITATION NOTICE
H -- Application of the mutagen sensitivity DNA repair assay in the Spanish Bladder Cancer Study
- Notice Date
- 8/17/2007
- Notice Type
- Solicitation Notice
- NAICS
- 541380
— Testing Laboratories
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd. EPS Suite 600, Rockville, MD, 20852, UNITED STATES
- ZIP Code
- 00000
- Solicitation Number
- Reference-Number-NCI-70141-NV
- Response Due
- 8/31/2007
- Archive Date
- 9/15/2007
- Description
- In accordance with simplified acquisition procedures the National Cancer Institute (NCI), Division of Cancer Epidemiology and Genetics (DCEG), Hormonal and Reproductive Epidemiology Branch (HREB) plans to procure on a sole source basis with the University of Texas, M.D. Anderson Cancer Center, 1155 Pressler Boulevard, Houston, Texas 77030 to analyze lymphocyte samples in order to assess ability to repair DNA damage, using the mutagen sensitivity DNA repair assay. The mutagen sensitivity DNA repair assays measure the number of chromatid breaks using metaphase spreads in lymphocyte cultures from 432 samples in the Spanish Bladder Cancer Study. The Spanish Bladder Cancer (SBC) study is an interdisciplinary collaborative effort between investigators at DCEG and epidemiologists and laboratory investigators at the Institut Municipal d'Investigacio' Me'dica (IMIM) in Barcelona, Spain. SBC is a large hospital-based case-control study with very high participation rates, high quality DNA, and detailed and innovative exposure assessment. The Spanish study combines state-of-the-art exposure assessment using a computer-assisted interview and collection of biological specimens. Using the SBC study we have been evaluating genetic susceptibility factors for bladder cancer and the interaction of those factors with environmental and occupational exposures. The University of Texas, M.D. Anderson Cancer Center shall: 1) Perform 432 mutagen sensitivity assays using cyropreserved lymphocytes provided by NCI investigators. Lymphocyte cells will be fixed and stained with Giemsa solution to visualize chromosomes. Fifty metaphase spreads will be examined in each sample to determine the number of chromatid breaks, and the average number of breaks per cell will be determined. A minimum of 50 well-spread metaphases per sample will be read. Detailed reading criteria and examples of various types of breakage have been developed; 2) Laboratory Data Quality control: Researchers performing the assays will be blinded to the subject case control lymphocyte samples. To evaluate assay reproducibility we will include blinded duplicate samples. A single brand of fetal calf serum and culture bottles will be used as culture medium. The lot numbers of all reagents and chemicals will be recorded. The incubator temperature and carbon dioxide concentration will also be recorded each day to ensure that the culture conditions are uniform. For the mutagen sensitivity assay readings, a single cytogenetist will perform the readings for each assay to minimize inter-reader variation. M.D. Anderson is uniquely qualified to perform this work. They have successfully performed these mutagen sensitivity assays on cryopreserved lymphocytes from bladder cancer cases and controls from their study population and has shown that these assays also indicate susceptibility differences between cancer cases and controls. The current request is the continuation and expansion of the previous effort to understand the role of DNA repair genetic variation as a susceptibility factor for bladder cancer risk. The mutagen sensitivity requires an experienced laboratory with a strong cell biology background because of the technical difficulties. M.D. Anderson pioneered and validated this state-of-the-art technology. In addition, M.D. Anderson mutagen sensitivity assays are not offered commercially and only they possess the unique expertise and resources for the mutagen sensitivity assays, which is crucial for the success of our ongoing efforts to identify susceptibility phenotypes and functional genetic variants associated with bladder cancer risk. This is not a solicitation for competitive quotations. However, if any interested party believes it can provide the above service, without introducing new variables into an ongoing research experiments it may submit a statement of capabilities. The statement of capabilities and any other information furnished must be in writing and must contain material in sufficient detail to allow NCI to determine if the party can perform the requirement. An original and one copy of the capability statements must be received in the contracting office by 1:00 p.m. EDT, on August 31, 2007. Faxed and emailed capability statements are NOT authorized. All questions must be in writing and can be faxed to (301) 402-4513 or emailed to dm170b@nih.gov. It is the vendor's responsibility to call (301) 402-4509 to verify questions have been received. A determination by the Government not to compete this proposed requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. In order to receive an award from the NCI contractors must be registered in the Online Representations and Certifications Applications (ORCA). Please refer to http://orca.bpn.gov in order to register. In addition, contractors must be registered in the Central Contractor Registration (CCR) www.ccr.gov. No collect calls will be accepted. NAICS 541380. Size Standard $11M.
- Record
- SN01376216-W 20070819/070817220638 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |